Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets

被引:42
作者
Barnes, CJ [1 ]
Kumar, R [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
关键词
EGFR; HER; signaling; therapy; cancer; review;
D O I
10.1023/A:1023726827771
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activating mutations, gene amplification and overexpression of human epidermal growth factor receptor (erbB or HER) family kinases have been implicated as integral contributors to a variety of cancers. However, there is increasing evidence that the HER family receptors propagate not only signals initiated by their own ligands but also those initiated by multiple other signaling pathways. Attenuation of HER family signaling is a developing strategy for the management of human malignancies and is the subject of a number of ongoing clinical trials. The purpose of this review is to provide a timely update of recent reports in the rapidly evolving area of HER family biology and the emerging integral role of these receptors in malignant transformation and as targets of cancer therapy.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 46 条
  • [1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    Agus, DB
    Akita, RW
    Fox, WD
    Lewis, GD
    Higgins, B
    Pisacane, PI
    Lofgren, JA
    Tindell, C
    Evans, DP
    Maiese, K
    Scher, HI
    Sliwkowski, MX
    [J]. CANCER CELL, 2002, 2 (02) : 127 - 137
  • [2] Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer
    Allen, LF
    Lenehan, PF
    Eiseman, IA
    Elliott, WL
    Fry, DW
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 11 - 21
  • [3] The plasminogen activation system in tumor growth, invasion, and metastasis
    Andreasen, PA
    Egelund, R
    Petersen, HH
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (01) : 25 - 40
  • [4] External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator
    Asada, S
    Choi, Y
    Yamada, M
    Wang, SC
    Hung, MC
    Qin, J
    Uesugi, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) : 12747 - 12752
  • [5] Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-β1-mediated angiogenesis
    Bagheri-Yarmand, R
    Vadlamudi, RK
    Wang, RA
    Mendelsohn, J
    Kumar, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (50) : 39451 - 39457
  • [6] Baker CH, 2002, CANCER RES, V62, P1996
  • [7] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
    Baselga, J
    Rischin, D
    Ranson, M
    Calvert, H
    Raymond, E
    Kieback, DG
    Kaye, SB
    Gianni, L
    Harris, A
    Bjork, T
    Averbuch, SD
    Feyereislova, A
    Swaisland, H
    Rojo, F
    Albanell, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4292 - 4302
  • [8] Structure of the extracellular region of HER3 reveals an interdomain tether
    Cho, HS
    Leahy, DJ
    [J]. SCIENCE, 2002, 297 (5585) : 1330 - 1333
  • [9] 1,25-dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor
    Cordero, JB
    Cozzolino, M
    Lu, Y
    Vidal, M
    Slatopolsky, E
    Stahl, PD
    Barbieri, MA
    Dusso, A
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (41) : 38965 - 38971
  • [10] The ErbB receptor family: a therapeutic target for cancer
    de Bono, JS
    Rowinsky, EK
    [J]. TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) : S19 - S26